FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:496-509 July 30, 2009 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Psoriasis is important to the clinician because it is common and has treatment implications beyond the care of skin lesions. It is important to the physician-scientist because it serves as a model for studies of mechanisms of chronic inflammation. It is important to the clinical-trial investigator because it is increasingly a first-choice disease indication for proof-of-principle studies of new pathogenesis-based therapeutic strategies.

In recent years, substantial advances have been made in elucidating the molecular mechanisms of psoriasis. However, major issues remain unresolved, including the primary nature of the disease as an epithelial or immunologic disorder, the autoimmune cause of the . . . [Full Text of this Article]

Epidemiologic Features and Clinicopathological Correlations

Genetic Factors

Immunopathologic Features of Psoriasis

The Innate Immune System and the Role of Keratinocytes

Dendritic Cells

T Cells

Cytokines

Counterregulatory Mechanisms

The Psoriatic Microvasculature

Models of Psoriasis

Psoriasis as a Systemic Inflammatory Disease

Pathogenesis-Based Approaches to Therapy

Conclusions

Source Information

From St. John's Institute of Dermatology, National Institute for Health Research Biomedical Research Centre, Cutaneous Medicine Theme and Federation of Clinical Immunology Societies Centre of Excellence at King's College London and Guy's and St. Thomas' Foundation Trust, London (F.O.N., J.B.); and the Department of Dermatology, Center for Immunology, University of Minnesota, Minneapolis (D.H.K.).

Address reprint requests to Dr. Nestle at St. John's Institute of Dermatology, Fl. 9, Guy's Tower Wing, Guy's Hospital, Great Maze Pond, London SE1 9RT, United Kingdom, or at frank.nestle@kcl.ac.uk.

Related Letters:

Psoriasis
Salem C. B., Hmouda H., Bouraoui K., Nestle F. O., Kaplan D., Barker J.
Extract | Full Text | PDF  
N Engl J Med 2009; 361:1710, Oct 22, 2009. Correspondence

This article has been cited by other articles:

• Theoharides, T. C., Zhang, B., Kempuraj, D., Tagen, M., Vasiadi, M., Angelidou, A., Alysandratos, K.-D., Kalogeromitros, D., Asadi, S., Stavrianeas, N., Peterson, E., Leeman, S., Conti, P. (2010). IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc. Natl. Acad. Sci. USA 107: 4448-4453 [Abstract] [Full Text]  
• Boehncke, W.-H., Boehncke, S., Schon, M. P (2010). Managing comorbid disease in patients with psoriasis. BMJ 340: b5666-b5666 [Full Text]  
• Salem, C. B., Hmouda, H., Bouraoui, K., Nestle, F. O., Kaplan, D., Barker, J. (2009). Psoriasis. NEJM 361: 1710-1710 [Full Text]  
• (2009). Briefly Noted. Journal Watch Dermatology 2009: 5-5 [Full Text]